



Press release

Half-yearly report on the liquidity contract with TP ICAP (Europe) SA

Under the liquidity contract entered into by ABIONYX Pharma with TP ICAP (Europe) SA, the following assets were included in the liquidity account at June 30, 2025:

- Number of shares: 162,298
- Cash balance: 86,279.52 €

During the 1st half of 2025, a total of :

PURCHASE	223,631 shares	275,707.78 €	253 transactions
SALE	214,077 shares	272,643.70 €	226 transactions

As a reminder, at the half-yearly balance sheet date of December 31, 2024, the following assets were included in the liquidity account:

- Number of shares: 152,744 shares
- Cash balance: 90,498.64 €

When the liquidity contract was set up, the following resources were made available:

- Number of shares: 131,000 shares
- Cash balance: 40,801.20 €

ABNX FP	Purchases			Sales		
	number of transactions	Number of shares	Capital in EUR	number of transactions	Number of shares	Capital in EUR
Total	253	223,631	275,707.78	226	214,077	272,643.696
20250101	0	0	0,00	0	0	0,00
20250102	1	1	1,20	1	1	1,20
20250103	4	4 731	5 598,24	1	1	1,20
20250106	2	2 151	2 555,39	1	1	1,19
20250107	2	2 091	2 475,76	2	2	2,41
20250108	1	1	1,21	6	16 781	20 838,45
20250109	1	1	1,28	3	4 091	5 261,22
20250110	5	6 674	8 375,50	1	1	1,30
20250113	2	2 321	2 915,20	1	1	1,28
20250114	2	2 251	2 827,26	1	1	1,26
20250115	3	2 283	2 834,77	2	1 364	1 732,25
20250116	2	2 181	2 708,83	2	54	68,58
20250117	1	1	1,27	5	12 861	16 681,79
20250120	2	2 411	3 134,32	3	4 051	5 396,12
20250121	4	5 141	6 583,61	1	1	1,29
20250122	2	2 391	3 003,11	1	1	1,27
20250123	2	2 321	2 910,53	2	98	125,61
20250124	2	2 251	2 827,28	2	3	3,85
20250127	3	3 001	3 731,25	1	1	1,25
20250128	1	1	1,24	1	1	1,24
20250129	4	3 726	4 523,13	1	1	1,24
20250130	2	300	362,40	1	1	1,21
20250131	2	16	19,30	4	8 891	11 103,15
20250203	3	3 141	3 830,03	2	72	90,00
20250204	2	2 251	2 710,21	1	1	1,21
20250205	1	1	1,22	2	2	2,44
20250206	2	2 181	2 630,31	1	1	1,23
20250207	2	2 131	2 544,42	1	1	1,20
20250210	1	1	1,22	2	2	2,44
20250211	1	1	1,20	1	1	1,20
20250212	1	1	1,20	4	6 289	7 736,41
20250213	3	3 011	3 659,43	2	2	2,49
20250214	1	1	1,23	2	2	2,46
20250217	2	250	300,50	3	4 441	5 480,40
20250218	1	1	1,24	4	4 329	5 463,59
20250219	3	3 201	3 941,54	2	392	494,68
20250220	1	1	1,33	6	15 961	21 228,13
20250221	1	1	1,31	2	738	972,68

20250224	3	3 621	4 697,72	1	1	1,32
20250225	1	1	1,33	5	11 351	15 354,69
20250226	3	3 811	5 134,77	3	3 591	4 962,95
20250227	3	3 821	5 140,51	1	1	1,35
20250228	4	5 691	7 466,21	1	1	1,35
20250303	1	1	1,30	6	12 891	17 168,66
20250304	4	6 181	8 071,89	2	2	2,69
20250305	2	2	2,54	2	1 559	2 023,55
20250306	2	2 921	3 727,21	1	1	1,29
20250307	3	3 871	4 913,61	1	1	1,27
20250310	3	3 721	4 715,77	1	1	1,27
20250311	4	5 571	6 855,74	1	1	1,26
20250312	1	1	1,24	1	1	1,24
20250313	2	424	517,30	3	4 051	5 072,04
20250314	3	3 571	4 439,97	1	1	1,25
20250317	2	2 561	3 129,56	1	1	1,24
20250318	1	1	1,24	1	1	1,24
20250319	2	2 481	3 031,78	1	1	1,22
20250320	2	2 411	2 941,43	3	4 231	5 297,39
20250321	1	1	1,26	7	19 891	25 919,78
20250324	3	3 627	4 672,00	2	972	1 281,10
20250325	2	2 901	3 690,09	1	1	1,29
20250326	1	1	1,29	1	1	1,29
20250327	1	1	1,28	1	1	1,28
20250328	1	1	1,28	1	1	1,28
20250331	2	1 862	2 346,13	1	1	1,27
20250401	5	9 031	11 067,11	1	1	1,27
20250402	4	5 341	6 540,66	1	1	1,24
20250403	3	3 301	4 051,43	1	1	1,23
20250404	5	7 581	9 022,58	1	1	1,24
20250407	7	10 871	12 406,55	1	1	1,19
20250408	2	1 338	1 493,23	5	9 741	11 244,94
20250409	4	4 202	4 770,74	1	1	1,14
20250410	1	1	1,18	5	13 821	16 335,50
20250411	2	2 451	2 857,87	1	1	1,17
20250414	2	911	1 060,43	2	2	2,38
20250415	2	2 351	2 741,29	1	1	1,19
20250416	2	640	744,96	1	1	1,16
20250417	1	1	1,19	2	2 231	2 659,35
20250418	0	0	0,00	0	0	0,00
20250421	0	0	0,00	0	0	0,00
20250422	1	1	1,20	3	4 481	5 386,40
20250423	1	1	1,19	3	4 321	5 280,47
20250424	1	1	1,23	2	413	508,82

20250425	1	1	1,21	1	1	1,21
20250428	1	1	1,23	2	249	306,27
20250429	2	2	2,44	1	1	1,23
20250430	2	1 865	2 256,68	1	1	1,24
20250501	0	0	0,00	0	0	0,00
20250502	1	1	1,22	2	2 071	2 551,46
20250505	6	10 811	12 763,44	1	1	1,24
20250506	3	3 021	3 629,31	2	2	2,46
20250507	1	1	1,23	1	1	1,23
20250508	1	1	1,21	1	1	1,21
20250509	1	1	1,23	1	1	1,23
20250512	3	2 191	2 629,20	1	1	1,20
20250513	1	1	1,23	2	4	4,93
20250514	1	1	1,23	1	1	1,23
20250515	1	1	1,23	1	1	1,23
20250516	2	2 061	2 493,83	1	1	1,23
20250519	1	1	1,23	1	1	1,23
20250520	1	1	1,21	4	9 071	11 364,29
20250521	1	1	1,24	2	2	2,49
20250522	1	1	1,24	3	4 371	5 455,20
20250523	1	1	1,26	4	8 381	10 768,00
20250526	1	1	1,30	2	2 001	2 601,30
20250527	1	1	1,31	4	7 871	10 396,13
20250528	1	1	1,33	3	3 579	4 767,23
20250529	4	6 071	7 774,61	1	1	1,29
20250530	1	1	1,29	1	1	1,29
20250602	1	1	1,30	2	474	619,98
20250603	1	1	1,31	1	1	1,31
20250604	3	3 771	4 839,51	1	1	1,29
20250605	1	1	1,26	1	1	1,26
20250606	1	1	1,28	1	1	1,28
20250609	1	1	1,28	1	1	1,28
20250610	1	1	1,29	2	1 951	2 520,69
20250611	3	3 002	3 833,87	1	1	1,30
20250612	3	3 621	4 589,10	1	1	1,30
20250613	3	3 511	4 400,52	1	1	1,26
20250616	2	300	372,00	1	1	1,24
20250617	1	1	1,25	1	1	1,25
20250618	2	961	1 180,13	1	1	1,25
20250619	1	1	1,25	1	1	1,25
20250620	2	2 491	3 058,95	1	1	1,23
20250623	3	3 301	4 031,62	1	1	1,22
20250624	1	1	1,23	1	1	1,23
20250625	2	2 361	2 852,09	1	1	1,21

20250626	1	1	1,23	1	1	1,23
20250627	1	1	1,23	1	1	1,23
20250630	4	4 761	5 678,38	1	1	1,20

About ABIONYX Pharma

ABIONYX Pharma is a new-generation biotechnology company whose aim is to contribute to healthcare through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to offer drugs for the treatment of kidney and ophthalmological diseases, or new apoA-1 vectors used for targeted drug delivery.

Contacts

NewCap

Investor Relations
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap

Media Relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15